JP2004508280A - 活性化プロテインｃ（ａｐｃ）の神経保護薬、抗血栓薬および抗炎症薬としての使用 - Google Patents

活性化プロテインｃ（ａｐｃ）の神経保護薬、抗血栓薬および抗炎症薬としての使用 Download PDF

Info

Publication number
JP2004508280A
JP2004508280A JP2001556226A JP2001556226A JP2004508280A JP 2004508280 A JP2004508280 A JP 2004508280A JP 2001556226 A JP2001556226 A JP 2001556226A JP 2001556226 A JP2001556226 A JP 2001556226A JP 2004508280 A JP2004508280 A JP 2004508280A
Authority
JP
Japan
Prior art keywords
apc
subject
disease
protein
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001556226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508280A5 (enExample
Inventor
グリフィン，ジョン，エイチ．
ズロコヴィック，ベリスラフ，ワイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
University of Southern California USC
Original Assignee
Scripps Research Institute
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute, University of Southern California USC filed Critical Scripps Research Institute
Publication of JP2004508280A publication Critical patent/JP2004508280A/ja
Publication of JP2004508280A5 publication Critical patent/JP2004508280A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001556226A 2000-02-04 2001-02-05 活性化プロテインｃ（ａｐｃ）の神経保護薬、抗血栓薬および抗炎症薬としての使用 Pending JP2004508280A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18022700P 2000-02-04 2000-02-04
PCT/US2001/003758 WO2001056532A2 (en) 2000-02-04 2001-02-05 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)

Publications (2)

Publication Number Publication Date
JP2004508280A true JP2004508280A (ja) 2004-03-18
JP2004508280A5 JP2004508280A5 (enExample) 2008-03-27

Family

ID=22659693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001556226A Pending JP2004508280A (ja) 2000-02-04 2001-02-05 活性化プロテインｃ（ａｐｃ）の神経保護薬、抗血栓薬および抗炎症薬としての使用

Country Status (8)

Country Link
US (1) US7074402B2 (enExample)
EP (1) EP1255556B1 (enExample)
JP (1) JP2004508280A (enExample)
AT (1) ATE504310T1 (enExample)
AU (1) AU2001238034A1 (enExample)
CA (1) CA2398929C (enExample)
DE (1) DE60144366D1 (enExample)
WO (1) WO2001056532A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096443A1 (en) * 2002-03-08 2004-05-20 Traynelis Stephen Francis Treatment of neurodegenerative diseases and conditions using par1 antagonists
EP1404412B1 (en) 2001-06-13 2012-03-21 The University of Sydney Protein C for wound healing
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1572134B1 (en) * 2002-09-30 2011-09-28 Zz Biotech L.L.C. Protein s for use as a neuroprotective agent
WO2004056309A2 (en) * 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
CA2508276C (en) * 2002-12-05 2018-03-27 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
US20080293631A1 (en) * 2005-01-07 2008-11-27 Christopher John Jackson Treatment for Autoimmune and Inflammatory Conditions
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
CA2693921A1 (en) 2007-07-20 2009-01-29 Genesys Venture Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
WO2009099642A2 (en) * 2008-02-05 2009-08-13 The Board Of Trustees Of The Leland Stanford Junior University Proteomic analysis of active multiple sclerosis lesions
CA2759490A1 (en) * 2009-04-22 2010-10-28 Sanomune Inc. Tissue kallikrein for the treatment of huntington's disease
WO2014005183A1 (en) 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
CN104122396A (zh) * 2013-04-23 2014-10-29 中国科学院上海生命科学研究院 维生素k依赖性蛋白s作为糖尿病标志物的应用
PT3131572T (pt) 2014-04-16 2021-09-24 Zz Biotech Llc Análogo de apc para utilização em cicatrização de feridas
PL3137102T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry
CN105806818B (zh) * 2016-04-01 2019-11-22 南京医科大学 检测血小板nmda受体活性的方法及其应用
EP3464322B1 (en) 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
WO2018165551A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1
JP7624238B2 (ja) * 2020-03-24 2025-01-30 タレンゲン インターナショナル リミテッド ハンチントン病を治療する方法及び薬剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238536A (ja) * 1987-11-17 1989-09-22 Scripps Clinic Res Found 動脈の血栓症的閉塞または塞栓症を阻止するための医薬組成物
JPH0338528A (ja) * 1989-06-26 1991-02-19 Immuno Ag Chem Med Prod 血栓症および血栓寒栓併発症を処置および予防するための調整物
WO1998042358A1 (en) * 1997-03-24 1998-10-01 Eli Lilly And Company Methods for treating vascular disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
KR20010013413A (ko) * 1997-06-05 2001-02-26 피터 지. 스트링거 혈전성 질환의 치료 방법
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238536A (ja) * 1987-11-17 1989-09-22 Scripps Clinic Res Found 動脈の血栓症的閉塞または塞栓症を阻止するための医薬組成物
JPH0338528A (ja) * 1989-06-26 1991-02-19 Immuno Ag Chem Med Prod 血栓症および血栓寒栓併発症を処置および予防するための調整物
WO1998042358A1 (en) * 1997-03-24 1998-10-01 Eli Lilly And Company Methods for treating vascular disorders

Also Published As

Publication number Publication date
WO2001056532A9 (en) 2003-01-09
CA2398929C (en) 2011-05-31
US20020028199A1 (en) 2002-03-07
ATE504310T1 (de) 2011-04-15
DE60144366D1 (de) 2011-05-19
EP1255556A2 (en) 2002-11-13
AU2001238034A1 (en) 2001-08-14
CA2398929A1 (en) 2001-08-09
EP1255556B1 (en) 2011-04-06
WO2001056532A3 (en) 2001-12-06
US7074402B2 (en) 2006-07-11
WO2001056532A2 (en) 2001-08-09
EP1255556A4 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
JP2004508280A (ja) 活性化プロテインｃ（ａｐｃ）の神経保護薬、抗血栓薬および抗炎症薬としての使用
US6315995B1 (en) Methods for treating an ischemic disorder and improving stroke outcome
AU735012B2 (en) Modified factor VII
US8119597B2 (en) Non-neurotoxic plasminogen activating factors for treating of stroke
JPH11500408A (ja) 改良型▲ｖｉｉ▼因子
JP4986618B2 (ja) 通常の細胞保護活性を有するが抗凝固活性が低下した活性化プロテインｃ変異体
JP2006525270A (ja) 脳梗塞の処置のための非神経毒性プラスミノーゲン活性剤の静脈内注射
JP2006525270A5 (enExample)
US20050250688A1 (en) Methods for treating an ischemic disorder and improving stroke outcome
CN103566362B (zh) 重组adamts13在制备脑出血药物中的用途
JP2012077090A (ja) 脳梗塞の処置のための非神経毒性プラスミノーゲン活性剤の静脈内注射
US20080057050A1 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20060135425A1 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
KR20010005626A (ko) 혈관 질환의 치료 방법
US20040087498A1 (en) Modified factor VII
Chen et al. Exploring the Therapeutic Potential of Tranexamic Acid for Traumatic Brain Injury: A Rat Model Study
JP2001505907A (ja) ｓｃｕＰＡ／ｓｕＰＡＲ複合体の医療への使用
WO2005074979A1 (fr) Utilisation de la prourokinase pour le traitement du syndrome pulmonaire thrombo-embolique ou de l'occlusion de l'artere centrale de la retine
JP2008507561A (ja) 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110804

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120327